Pharm-Olam is now Allucent. Learn More
Filter by Type:
Filter by Topic:
A Pharm-Olam case study of a Phase I/II pediatric Respiratory Distress Syndrome neonate study with a gestational age between 27 and 33 weeks.
2 min. Read
In this Phase III study, Pharm-Olam partnered with a progressive sponsor company to assist in finding a better solution for suffering with ...
3 min. read
Pharm-Olam provided a complete enrollment solution for the management and data submission of this Acute Bacterial Skin and Skin Structure ...
A Pharm-Olam overview of Allergic Rhinitis based on two decades of study experience.
2 min. read
Pharm-Olam partnered with a sponsor company on a Phase II/III study for the treatment of Recurrent Glioblastoma / Anaplastic Astrocytoma.
Pharm-Olam partnered with a sponsor company on a Phase II Birch Allergy Immunotherapy study to research the viability of new allergy ...
We'll only send you one email a month featuring our best content from the month before.